{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:06:41Z","timestamp":1773976001635,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T00:00:00Z","timestamp":1355788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40262-012-0024-7","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T15:36:51Z","timestamp":1355758611000},"page":"139-151","source":"Crossref","is-referenced-by-count":82,"title":["Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects"],"prefix":"10.1007","volume":"52","author":[{"given":"Luis","family":"Almeida","sequence":"first","affiliation":[]},{"given":"Jos\u00e9 Francisco","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"P.","family":"Nuno Palma","sequence":"additional","affiliation":[]},{"given":"Ana I.","family":"Loureiro","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Bonif\u00e1cio","sequence":"additional","affiliation":[]},{"given":"Lyndon C.","family":"Wright","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,12,18]]},"reference":[{"issue":"3","key":"24_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/14728214.11.3.403","volume":"11","author":"JC Morgan","year":"2006","unstructured":"Morgan JC, Sethi KD. Emerging drugs for Parkinson\u2019s disease. Expert Opin Emerg Drugs. 2006;11(3):403\u201317.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"9","key":"24_CR2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1468-1331.2009.02697.x","volume":"16","author":"AH Schapira","year":"2009","unstructured":"Schapira AH, Emre M, Jenner P, et al. Levodopa in the treatment of Parkinson\u2019s disease. Eur J Neurol. 2009;16(9):982\u20139.","journal-title":"Eur J Neurol"},{"key":"24_CR3","first-page":"415","volume-title":"Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies","author":"PN Palma","year":"2007","unstructured":"Palma PN, Bonif\u00e1cio MJ, Almeida L, et al. Restoring dopamine levels. In: Simth HJ, Simons C, Sewell RDE, editors. Protein misfolding in neurodegenerative diseases: mechanisms and therapeutic strategies. Boca Raton: CRC Press; 2007. p. 415\u201345."},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1527-3458.2007.00020.x","volume":"13","author":"MJ Bonif\u00e1cio","year":"2007","unstructured":"Bonif\u00e1cio MJ, Palma PN, Almeida L, et al. Catechol-O-methyltransferase and its inhibitors in Parkinson\u2019s disease. CNS Drug Rev. 2007;13:352\u201379.","journal-title":"CNS Drug Rev"},{"issue":"6","key":"24_CR5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ana.410210610","volume":"21","author":"JG Nutt","year":"1987","unstructured":"Nutt JG, Woodward WR, Gancher ST, et al. 3-O-methyldopa and the response to levodopa in Parkinson\u2019s disease. Ann Neurol. 1987;21(6):584\u20138.","journal-title":"Ann Neurol"},{"issue":"1","key":"24_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000116905","volume":"33","author":"P Benetello","year":"1993","unstructured":"Benetello P, Furlanut M, Zara G, et al. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. Eur Neurol. 1993;33(1):69\u201373.","journal-title":"Eur Neurol"},{"issue":"1","key":"24_CR7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0024-3205(75)90248-9","volume":"17","author":"LA Wade","year":"1975","unstructured":"Wade LA, Katzman R. 3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci. 1975;17(1):131\u20136.","journal-title":"Life Sci"},{"issue":"3","key":"24_CR8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.33.3.278","volume":"33","author":"JJ Gervas","year":"1983","unstructured":"Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology. 1983;33(3):278\u201382.","journal-title":"Neurology"},{"issue":"9","key":"24_CR9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0028-3908(99)00042-8","volume":"38","author":"P Gomes","year":"1999","unstructured":"Gomes P, Soares-da-Silva P. Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology. 1999;38(9):1371\u201380.","journal-title":"Neuropharmacology"},{"issue":"5","key":"24_CR10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/00003088-200140050-00005","volume":"40","author":"H Baas","year":"2001","unstructured":"Baas H, Zehrden F, Selzer R, et al. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson\u2019s disease. Clin Pharmacokinet. 2001;40(5):383\u201393.","journal-title":"Clin Pharmacokinet"},{"key":"24_CR11","doi-asserted-by":"crossref","unstructured":"Muller T, Kolf K, Ander L, et al. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Clin Neuropharmacol 2008;31(3):134\u201340.","DOI":"10.1097\/WNF.0b013e31811510ed"},{"issue":"4","key":"24_CR12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/phrs.1997.0145","volume":"35","author":"P Benetello","year":"1997","unstructured":"Benetello P, Furlanut M, Fortunato M, et al. Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res. 1997;35(4):313\u20135.","journal-title":"Pharmacol Res"},{"issue":"6","key":"24_CR13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ana.410310611","volume":"31","author":"M Guttman","year":"1992","unstructured":"Guttman M, Leger G, Cedarbaum JM, et al. 3-O-methyldopa administration does not alter fluorodopa transport into the brain. Ann Neurol. 1992;31(6):638\u201343.","journal-title":"Ann Neurol"},{"issue":"10","key":"24_CR14","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/BF01923483","volume":"50","author":"N Himori","year":"1994","unstructured":"Himori N, Mishima K. The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice. Experientia. 1994;50(10):939\u201342.","journal-title":"Experientia"},{"issue":"2","key":"24_CR15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00199880","volume":"46","author":"T Keranen","year":"1994","unstructured":"Keranen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol. 1994;46(2):151\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"24_CR16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/0009-9236(95)90035-7","volume":"57","author":"J Dingemanse","year":"1995","unstructured":"Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther. 1995;57(5):508\u201317.","journal-title":"Clin Pharmacol Ther"},{"issue":"5 Suppl 5","key":"24_CR17","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1212\/WNL.50.5_Suppl_5.S46","volume":"50","author":"H Baas","year":"1998","unstructured":"Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the \u201cwearing off\u201d phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology. 1998;50(5 Suppl 5):S46\u201353.","journal-title":"Neurology"},{"issue":"5","key":"24_CR18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00228-009-0622-y","volume":"65","author":"M Kuoppamaki","year":"2009","unstructured":"Kuoppamaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa\/carbidopa\/entacapone and levodopa\/carbidopa when administered four or five times daily. Eur J Clin Pharmacol. 2009;65(5):443\u201355.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1 Suppl 1","key":"24_CR19","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/WNL.62.1_suppl_1.S39","volume":"62","author":"DJ Brooks","year":"2004","unstructured":"Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology. 2004;62(1 Suppl 1):S39\u201346.","journal-title":"Neurology"},{"key":"24_CR20","unstructured":"Dingemanse J. Issues important for rational COMT inhibition. Neurology. 2000;55 (11 Suppl 4):S24-7; discussion S8-32."},{"issue":"Suppl 4","key":"24_CR21","first-page":"S45","volume":"17","author":"AE Lang","year":"2002","unstructured":"Lang AE, Lees A. Management of Parkinson\u2019s disease: an evidence-based review. Mov Disord. 2002;17(Suppl 4):S45\u201351.","journal-title":"Mov Disord"},{"issue":"12","key":"24_CR22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1468-1331.2009.02726.x","volume":"16","author":"H Nissinen","year":"2009","unstructured":"Nissinen H, Kuoppamaki M, Leinonen M, et al. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson\u2019s disease: a long-term, retrospective analysis. Eur J Neurol. 2009;16(12):1305\u201311.","journal-title":"Eur J Neurol"},{"key":"24_CR23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1755-5949.2010.00145.x","volume":"16","author":"JJ Ferreira","year":"2010","unstructured":"Ferreira JJ, Rascol O, Poewe W, et al. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson\u2019s disease. CNS Neurosci Ther. 2010;16:337\u201347.","journal-title":"CNS Neurosci Ther"},{"key":"24_CR24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/B978-0-12-381326-8.00006-5","volume":"95","author":"DA Learmonth","year":"2010","unstructured":"Learmonth DA, Kiss LE, Soares-da-Silva P. The chemistry of catechol-O-methyltransferase inhibitors. Int Rev Neurobiol. 2010;95:119\u201362.","journal-title":"Int Rev Neurobiol"},{"issue":"8","key":"24_CR25","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1021\/jm1001524","volume":"53","author":"LE Kiss","year":"2010","unstructured":"Kiss LE, Ferreira HS, Torrao L, et al. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2010;53(8):3396\u2013411.","journal-title":"J Med Chem"},{"issue":"9","key":"24_CR26","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jcc.22926","volume":"33","author":"PN Palma","year":"2012","unstructured":"Palma PN, Bonif\u00e1cio MJ, Loureiro AI, et al. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem. 2012;33(9):970\u201386.","journal-title":"J Comput Chem"},{"key":"24_CR27","doi-asserted-by":"crossref","unstructured":"Bonif\u00e1cio MJ, Sutcliffe JS, Torr\u00e3o L, et al. Brain and peripheral levodopa pharmacokinetics in the Cynomolgus monkey following administration of opicapone, a novel catechol-O-methyltransferase inhibitor. Parkinsonism Relat D. 2012;18(S2):S125.","DOI":"10.1016\/S1353-8020(11)70566-1"},{"key":"24_CR28","doi-asserted-by":"crossref","unstructured":"Bonif\u00e1cio MJ, Torr\u00e3o L, Loureiro AI, et al. Opicapone: characterization of a novel peripheral long-acting catechol-O-methyltransferase inhibitior. Parkinsonism Relat D 2012;18(S2):S125.","DOI":"10.1016\/S1353-8020(11)70567-3"},{"key":"24_CR29","unstructured":"Data on file, Bial, 2012."},{"key":"24_CR30","unstructured":"FDA\/CDER. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in healthy adult volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Rockville: FDA\/CDER; 2005."},{"issue":"2","key":"24_CR31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/bmc.1130030205","volume":"3","author":"E Schultz","year":"1989","unstructured":"Schultz E, Nissinen E, Kaakkola S. Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed Chromatogr. 1989;3(2):64\u20137.","journal-title":"Biomed Chromatogr"},{"key":"24_CR32","unstructured":"FDA\/CDER. Guidance for industry (draft). Food-effect bioavailability and fed bioequivalence studies: study design, data analysis, and labeling. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Rockville: FDA\/CDER; 2001."},{"issue":"8\u20139","key":"24_CR33","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00228-003-0680-5","volume":"59","author":"P Silveira","year":"2003","unstructured":"Silveira P, Vaz-da-Silva M, Almeida L, et al. Pharmacokinetic-pharmacodynamic interaction between BIA 3\u2013202, a novel COMT inhibitor, and levodopa\/benserazide. Eur J Clin Pharmacol. 2003;59(8\u20139):603\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"24_CR34","unstructured":"Data on file, Bial, 2008."},{"key":"24_CR35","doi-asserted-by":"crossref","unstructured":"Ferreira JJ, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol. 2008;31(1):2\u201318.","DOI":"10.1097\/wnf.0b013e3180645cb0"},{"key":"24_CR36","doi-asserted-by":"crossref","unstructured":"Copeland RA, Pompliano D. Drug\u2013target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;1\u201310.","DOI":"10.1038\/nrd2082"},{"key":"24_CR37","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1021\/bi8002023","volume":"47","author":"PJ Tummino","year":"2008","unstructured":"Tummino PJ, Copeland RA. Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry. 2008;47:5481\u201392.","journal-title":"Biochemistry"},{"key":"24_CR38","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2006.05.001","volume":"27","author":"G Vauquelin","year":"2006","unstructured":"Vauquelin G, Van Liefde I. Slow antagonist dissociation and long-lasting in vivo receptor protection. Trends Pharmacol Sci. 2006;27:356\u20139.","journal-title":"Trends Pharmacol Sci"},{"key":"24_CR39","doi-asserted-by":"crossref","unstructured":"Palma PN, Bonif\u00e1cio MJ, Loureiro AI, et al. Computation of binding affinity of catechol-O-methyltransferase: opicapone complex. Parkinsonism Relat D 2012;18 (S2):S125.","DOI":"10.1016\/S1353-8020(11)70565-X"},{"key":"24_CR40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/368354a0","volume":"368","author":"J Vidgren","year":"1994","unstructured":"Vidgren J, Svensson LA, Liljas A. Crystal structure of catechol O-methyltransferase. Nature. 1994;368:354\u20138.","journal-title":"Nature"},{"key":"24_CR41","doi-asserted-by":"crossref","unstructured":"Rocha JF, Nunes T, Vaz-da-silva M, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel COMT inhibitor, during multiple rising dose regimens in healthy male subjects [abstract]. Parkinsonism Relat D 2012;18 (S2):S126.","DOI":"10.1016\/S1353-8020(11)70569-7"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-012-0024-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0024-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T00:26:06Z","timestamp":1562459166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-012-0024-7"}},"subtitle":["Prediction of Slow Enzyme\u2013Inhibitor Complex Dissociation of a Short-Living and Very Long-Acting Inhibitor"],"short-title":[],"issued":{"date-parts":[[2012,12,18]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s40262-012-0024-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,18]]}}}